HDAC6 and cancer: Furthermore, combining HDAC6 or AURA inhibitors with inhibitors of other pathways overactive in cancer cells, such as WNT or GFR (growth factor receptor) signaling [255], can more effectively halt cancer progression and potentially overcome resistance to single-pathway inhibitors.